Psychedelic-Assisted Therapy
2022 on combining ACT therapy with [psychedelics].
Mathai, D. S., Mora, V., & Garcia-Romeu, A. (2022). Toward Synergies of [Psychedelics] and Psychotherapy. Frontiers in Psychology, 1203.
2022 systematic narrative review of [psychedelic]-assisted psychotherapy.
Drozdz, S. J., Goel, A., McGarr, M. W., Katz, J., Ritvo, P., Mattina, G. F., … & Ladha, K. S. (2022). [Psychedelic] Assisted Psychotherapy: A Systematic Narrative Review of the Literature. Journal of Pain Research, 15, 1691.
2022 therapy augments effects of [psychedelics] for alcohol use disorder.
Grabski, M., McAndrew, A., Lawn, W., Marsh, B., Raymen, L., Stevens, T., … & Morgan, C. J. A. (2022). Adjunctive [Psychedelics] With Relapse Prevention-Based Psychological Therapy in the Treatment of Alcohol Use Disorder. The American Journal of Psychiatry, appiajp202121030277-appiajp202121030277.
2022 optimizing [psychedelic] treatment with trauma-informed psychotherapy.
Muscat, S. A., Hartelius, G., Crouch, C. R., & Morin, K. W. (2022). Optimized Clinical Strategies for Treatment-Resistant Depression: Integrating [Psychedelic] Protocols with Trauma-and Attachment-Informed Psychotherapy. Psych, 4(1), 119-141.
2021 therapy enhances durability of treatment effect.
Wilkinson, Samuel T., et al. “Cognitive behavioral therapy to sustain the antidepressant effects of [psychedelics] in treatment-resistant depression: a randomized clinical trial.” Psychotherapy and psychosomatics 90.5 (2021): 318-327.
2019 mindfulness-based therapy enhances positive effects with cocaine dependence.
Dakwar, Elias, et al. “A single [psychedelic] infusion combined with mindfulness-based behavioral modification to treat cocaine dependence: a randomized clinical trial.” American Journal of Psychiatry.
Psychedelics & Depression
2021 narrative review of [Psychedelics] for depression.
Jelen, Luke A., and James M. Stone. “[Psychedelics] for depression.” International Review of Psychiatry 33.3 (2021): 207-228.
2021 international expert opinion.
McIntyre, Roger S., et al. “Synthesizing the evidence for [Psychedelics] in treatment-resistant depression: an international expert opinion on the available evidence and implementation.” American Journal of Psychiatry 178.5 (2021): 383-399.
2021 systematic review of 83 trials.
Walsh, Zach, et al. “[Psychedelics] for the treatment of mental health and substance use disorders: comprehensive systematic review.” BJPsych Open 8.1 (2022).
2021 systematic review and meta-analysis.
Bahji, Anees, Gustavo H. Vazquez, and Carlos A. Zarate Jr. “Comparative efficacy of racemic [Psychedelics] for depression: a systematic review and meta-analysis.” Journal of affective disorders 278 (2021): 542-555.
Krystal, John H., et al. “[Psychedelics]: a paradigm shift for depression research and treatment.” Neuron 101.5 (2019): 774-778.
2017 consensus from the American Psychiatric Association.
Sanacora, Gerard, et al. “A consensus statement on the use of [Psychedelics] in the treatment of mood disorders.” JAMA psychiatry 74.4 (2017): 399-405.
Psychedelics, Anxiety, PTSD & OCD
Feder, Adriana, et al. “A randomized controlled trial of repeated [Psychedelics] administration for chronic posttraumatic stress disorder.” American Journal of Psychiatry 178.2 (2021): 193-202.
2021 review of [Psychedelics] for PTSD and putative mechanisms.
Asim, Muhammad, et al. “[Psychedelics] For Post-Traumatic Stress Disorders And It’s Possible Therapeutic Mechanism.” Neurochemistry International (2021): 105044.
2021 review for addiction, OCD and eating disorders.
Martinotti, Giovanni, et al. “Therapeutic Potentials of [Psychedelics] in Obsessive–Compulsive Disorder (OCD), Substance Use Disorders (SUD) and Eating Disorders (ED): A Review of the Current Literature.” Brain Sciences 11.7 (2021): 856.
2020 review for the treatment of anxiety disorders.
Banov, Michael D., et al. “Efficacy and safety of [Psychedelics] in the management of anxiety and anxiety spectrum disorders: a review of the literature.” CNS spectrums 25.3 (2020): 331-342.
2020 review of [Psychedelics] for PTSD
Feder, Adriana, et al. “The emergence of [Psychedelics] as a novel treatment for posttraumatic stress disorder.” Advances in Pharmacology 89 (2020): 261-286.
2020 review for the treatment of OCD.
Sharma, Lavanya P., et al. “Clinical utility of repeated intravenous [Psychedelics] treatment for resistant obsessive-compulsive disorder.” Asian journal of psychiatry 52 (2020): 102183.
​
Psychedelics & Addiction
2022 systematic review of 83 trials.
Walsh, Zach, et al. “[Psychedelics] for the treatment of mental health and substance use disorders: comprehensive systematic review.” BJPsych Open 8.1 (2022).
2021 review for alcohol use disorder.
Worrell, Stephen D., and Thomas J. Gould. “Therapeutic Potential of [Psychedelics] for Alcohol Use Disorder.” Neuroscience & Biobehavioral Reviews (2021).
2021 review for addiction, OCD and eating disorders.
Martinotti, Giovanni, et al. “Therapeutic Potentials of [Psychedelics] in Obsessive–Compulsive Disorder (OCD), Substance Use Disorders (SUD) and Eating Disorders (ED): A Review of the Current Literature.” Brain Sciences 11.7 (2021): 856.
2021 [Psychedelics] for cannabis use disorder.
Azhari, Nour, et al. “[Psychedelics]-facilitated behavioral treatment for cannabis use disorder: a proof of concept study.” The American journal of drug and alcohol abuse 47.1 (2021): 92-97.
2019 RCT for cocaine dependence.
Dakwar, Elias, et al. “A single [Psychedelics] infusion combined with mindfulness-based behavioral modification to treat cocaine dependence: a randomized clinical trial.” American Journal of Psychiatry 176.11 (2019): 923-930.
2019 RCT for cocaine use disorder.
Dakwar, E., et al. “Cocaine self-administration disrupted by the N-methyl-D-aspartate receptor antagonist [Psychedelics]: a randomized, crossover trial.” Molecular psychiatry 22.1 (2017): 76-81.
2018 systematic review of [Psychedelics] for substance use disorders.
Jones, Jennifer L., et al. “Efficacy of [Psychedelics] in the treatment of substance use disorders: a systematic review.” Frontiers in psychiatry 9 (2018): 277.
Clinical Trials
2022 systematic review of 83 trials.
Walsh, Zach, et al. “[Psychedelics] for the treatment of mental health and substance use disorders: comprehensive systematic review.” BJPsych Open 8.1 (2022).
2021 review of neurobiological mechanisms.
Kohtala, Samuel. “[Psychedelics]—50 years in use: from anesthesia to rapid antidepressant effects and neurobiological mechanisms.” Pharmacological Reports (2021): 1-23.
2020 safety review of 6630 patients.
Feifel, David, David Dadiomov, and Kelly C Lee. “Safety of repeated administration of parenteral [Psychedelics] for depression.” Pharmaceuticals 13.7 (2020): 151.
2018 blood pressure safety review.
Riva-Posse, Patricio, et al. “Blood pressure safety of subanesthetic [Psychedelics] for depression: a report on 684 infusions.” Journal of affective disorders 236 (2018): 291-297.
2017 review on ethics and safety.
Singh, I., Morgan, C., Curran, V., Nutt, D., Schlag, A., & McShane, R. (2017). [Psychedelics] treatment for depression: opportunities for clinical innovation and ethical foresight. The Lancet Psychiatry, 4(5), 419-426.
​